To demonstrate that 22.0405.aF can kill primary B-CLL cells, PBMCs from patients with B-CLL (n = 3), containing 65%–99% ROR1-positive malignant B-lymphocytic cells, were co-cultured with healthy donor-derived NK cells in the presence or absence of various concentrations of 22.0405.aF, zilovertamab-like antibody, or rituximab. Here, ROR1 is linked to B-cell chronic lymphocytic leukemia.